Actively Recruiting
Phase 1 Open-Label Crossover Study Comparing Different Oral Capsule Forms of Varegacestat in Healthy Adults
Led by Immunome, Inc. · Updated on 2026-10-29
44
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1, open-label, randomized crossover study to evaluate the relative bioavailability and bioequivalence of different capsule formulations of varegacestat in healthy adult volunteers. The study aims to compare the test capsule formulations with a reference capsule formulation under fasting conditions to understand how the drug is absorbed and processed in the body. Participants will receive oral doses of varegacestat in various formulations, including a reference formulation and three different test formulations A, B, and C. The study is designed in two parts, where participants receive one formulation followed by another in a randomized sequence. This approach allows direct comparison of the drug absorption from different capsule forms. During the study, participants will undergo evaluations for drug concentration in the blood at multiple time points to assess bioavailability. Safety assessments will include monitoring for adverse events, laboratory tests, vital signs, and ECGs. The entire study participation lasts approximately 3 to 4 weeks, during which participants will have scheduled visits for dosing and assessments to ensure safety and collect necessary data.
CONDITIONS
Brief Title
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
Research Team
I
Immunome Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here